| Code | 2609E | ||||||||||
| MA number | 44/0318/22-S | ||||||||||
| Product Form: | con inf 1x3 ml/60 mg (liek.inj.skl.) | ||||||||||
| MA Status: | R - Valid Marketing Authorisation | ||||||||||
| Type of procedure: | Decentralised | ||||||||||
| MAH, country: | Fresenius Kabi s.r.o., Czechia | ||||||||||
| Therapeutic Class: | 44 - CYTOSTATICA | ||||||||||
| ATC: |
|
||||||||||
| Shelf life: | 36 | ||||||||||
| Container: | glass vial | ||||||||||
| Route of admin.: | Intravenous use |
| Prescription Status: | Medicinal product subject to restricted medical prescription. |
| Legal basis: | Article 10(3) hybrid application |
| MA issued: | 27.12.2022 |
| Validity: | 27.12.2027 |
| SPC: |
SPC_Cabazitaxel Fresenius Kabi 20 mg_ml_09.2025.pdf
|
| PIL: |
PIL_Cabazitaxel Fresenius Kabi 20 mg_ml_09.2025.pdf
|
| Safety feature | Yes |
| Data update: | 09.01.2023 |
